Location · Greenville, SC
Clinical trials in Greenville, SC
78 recruiting studies have a site in Greenville, and 11 of them accept healthy volunteers.
78 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- Recruiting
Managing Pain Using Optimized Sequences by Adjusting Parameters With Independent Current Control
Boston Scientific Corporation
- Location
- Greenville, SC + 6 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Novartis Pharmaceuticals
- Location
- Greenville, SC + 42 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
Regeneron Pharmaceuticals
- Location
- Greenville, SC + 20 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
The Artisse™ Intrasaccular Device is Indicated for the Treatment of Wide-neck Bifurcating Intracranial Aneurysms (IAs).
Medtronic Neurovascular Clinical Affairs
- Location
- Greenville, SC + 24 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Incyte Corporation
- Location
- Greenville, SC + 36 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
GlaxoSmithKline
- Location
- Greenville, SC + 2 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
W.L.Gore & Associates
- Location
- Greenville, SC + 20 other US sites
- Eligibility basics
- Ages 18–90
- RecruitingPhase 2
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
Eli Lilly and Company
- Location
- Greenville, SC + 36 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 2
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
Eli Lilly and Company
- Location
- Greenville, SC + 39 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Eli Lilly and Company
- Location
- Greenville, SC + 42 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Eli Lilly and Company
- Location
- Greenville, SC + 36 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Eli Lilly and Company
- Location
- Greenville, SC + 34 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation
GlaxoSmithKline
- Location
- Greenville, SC + 36 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 3
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
Amgen
- Location
- Greenville, SC + 69 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 3
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
AstraZeneca
- Location
- Greenville, SC + 30 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1/Phase 2
HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction
35Pharma Inc
- Location
- Greenville, SC + 1 other US site
- Eligibility basics
- Ages 18+
- RecruitingPhase 2/Phase 3
Nectero EAST System Clinical Study
Nectero Medical, Inc.
- Location
- Greenville, SC + 35 other US sites
- Eligibility basics
- Ages 21–85
- RecruitingPhase 2
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Takeda
- Location
- Greenville, SC + 23 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
Pfizer
- Location
- Greenville, SC + 12 other US sites
- Eligibility basics
- Ages 6–11
- RecruitingPhase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Eli Lilly and Company
- Location
- Greenville, SC + 40 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
TG Therapeutics, Inc.
- Location
- Greenville, SC + 4 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2/Phase 3
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
Vertex Pharmaceuticals Incorporated
- Location
- Greenville, SC + 26 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2/Phase 3
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
DiaMedica Therapeutics Inc
- Location
- Greenville, SC + 35 other US sites
- Eligibility basics
- Ages 18–90
- RecruitingPhase 3
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie
- Location
- Greenville, SC + 87 other US sites
- Eligibility basics
- Ages 6–17